Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Dawn James

Clinical Nurse Specialist, Chronic Care Burlington, CO Nurse Practitioner

NPI 1669666269 CMS profile 11157079

54188 County Road Hh, Burlington, CO 80807

Open in the dashboard

General payments

$478

5 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dawn James of Burlington, CO is reported in the CMS Open Payments database as having received $478 across 5 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $149 1
2024 General $26 1
2023 General $18 1
2022 General $285 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dawn James
  • Colorado median
  • Middle half of Colorado
  • National median

In program year 2025, general payments to Dawn James were reported at $149. Among 17,059 Colorado profiles paid that year, the median was $144 and the middle half received between $41 and $532.

Show as a table
Year Dawn James Colorado median Middle half National median
2019 $0 $137 $40–$561 $163
2020 $0 $109 $32–$371 $114
2021 $0 $127 $33–$475 $132
2022 $285 $136 $40–$504 $149
2023 $18 $144 $43–$511 $160
2024 $26 $144 $42–$500 $164
2025 $149 $144 $41–$532 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Dexcom, Inc. $262 3 payments
  2. Medtronic, Inc. $190 1 payment
  3. PROCEPT BioRobotics Corporation $26 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $478 5 payments
Products named General payments · program years 2022–2025
  1. DEXCOM G7 GSS (161) $149 1 payment
  2. Dexcom G6 Transmitter $113 2 payments
  3. AQUABEAM SYSTEM $26 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$27,199

Of which drugs: $17,598

Medicare patients

146

Average age 75

Services billed

487

83 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 44%
Diabetes 40%
COPD 20%
Ischemic heart disease 18%
Heart failure 16%
Chronic kidney disease 16%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 84 96 $12,230
Vaccine for influenza for injection into muscle 90662 Office 34 34 $2,782
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 31 31 $664

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

5 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record